Figure 5
Puma expression in human MDS and phenotype of NHD13;Puma−/− mice. (a) Puma mRNA expression levels for WT, NHD13, p53 KO and NHD13; p53 KO mice (n=3). Results are expressed relative to actin and HPRT. (b) Puma gene expression in human MDS—data have been extracted from Pellagatti et al.44 and separate MDS into low-risk del(5q) and RARS and higher risk RAEB2. (c) Absolute quantification of LK and LSK subsets per mouse leg based on flow-cytometric analysis (n=9 per genotype). (d) Results from flow-cytometric analysis showing relative quantification of LK, LSK and SLAM subsets. Results are expressed as percentages of total nucleated cells. Plots shown are a single representation of three individual experiments. (e) Apoptosis of LSK stem cells as measured by staining for activated caspase-3/7, with data expressed relative to levels seen in WT mice (n=11 per genotype; 4 independent experiments). (f) In vitro colony assays—BFU-E (n=5 per genotype) and GMP (n=4 per genotype). Data have been normalized to wild-type numbers; *P<0.05; **P<0.01; ***P<0.001
